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Abbreviations: cAMP, cyclic AMP; cGMP, cyclic GMP; [cGMP]i, intracellular cGMP;DMSO, 
dimethylsufoxide; GC-C, guanylyl cyclase C; IBMX, isobutylmethylxanthine; PI, propidium 
iodide; PDE, phosphodiesterase; PKA, cAMP-dependent protein kinase; PKG II, cGMP-
dependent protein kinase II; ST, Escherichia coli heat-stable enterotoxin; TUNEL, terminal 
deoxynucleotidyl transferase-mediated dNTP-biotin nick end labeling of DNA fragments.
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ABSTRACT 
The effects of E. coli heat-stable enterotoxin (ST) and uroguanylin were examined on the 
proliferation of T84 and Caco-2 human colon carcinoma cells that express guanylyl cyclase C 
(GC-C) and SW480 human colon carcinoma cells that do not express this receptor. ST or 
uroguanylin inhibited proliferation of T84 and Caco-2 cells, but not SW480 cells, in a 
concentration-dependent fashion, assessed by quantifying cell number, cell protein, and 
3
H-
thymidine incorporation into DNA. These agonists did not inhibit proliferation by induction of 
apoptosis, assessed by TUNEL assay and DNA laddering, or necrosis, assessed by trypan blue 
exclusion and lactate dehydrogenase release. Rather, ST prolonged the cell cycle, assessed by 
flow cytometry and 
3
H-thymidine incorporation into DNA. The cytostatic effects of GC-C 
agonists were associated with accumulation of intracellular cGMP, mimicked by the cell-
permeant analog 8-Br-cGMP, and reproduced and potentiated by the cGMP-specific 
phosphodiesterase inhibitor zaprinast but not the inactive ST analog TJU 1-103. Thus, GC-C 
agonists regulate the proliferation of intestinal cells through cGMP-dependent mechanisms by 
delaying progression of the cell cycle. These data suggest that endogenous agonists of GC-C, 
such as uroguanylin, may play a role in regulating the balance between epithelial proliferation 
and differentiation in normal intestinal physiology. Therefore, GC-C ligands may be novel 
therapeutic agents for the treatment of patients with colorectal cancer. 
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INTRODUCTION 
STs
1
 are a family of homologous peptides produced by bacteria that cause diarrhea in travelers, 
under-developed countries, and farm animals (1-4). ST induces intestinal secretion by binding to 
GC-C, a single transmembrane protein that is expressed exclusively in the brush border of 
intestinal epithelial cells from the duodenum to the rectum in adult humans (5-10). Toxin 
interaction with the extracellular domain activates the cytoplasmic catalytic domain of GC-C 
inducing accumulation of [cGMP]i (11). This cyclic nucleotide activates PKG II, which 
phosphorylates the cystic fibrosis transmembrane conductance regulator increasing chloride 
transport, and inhibits electroneutral sodium absorption, resulting in fluid and electrolyte 
secretion in the intestine and diarrhea (11-13). 
STs are an example of molecular mimicry wherein bacteria have developed an evolutionarily 
advantageous strategy that exploits mechanisms regulating normal intestinal physiology. STs are 
members of a larger family of peptides that include guanylin and uroguanylin, GC-C agonists 
produced endogenously in mammalian gut (14-17). These peptides share sequence homology, 
have a tertiary structure stabilized by intrachain disulfide bonds, and exert their 
(patho)physiological effects by binding to GC-C and inducing cGMP accumulation. 
Uroguanylin, which is highly expressed in stomach, duodenum and jejunum, is 100-fold more 
potent than guanylin at acidic pH (18, 19). In contrast, guanylin is more abundant in ileum and 
colon and is 4-fold more potent than uroguanylin at a pH of 8.0 (18, 19). These endogenous GC-
C agonists may regulate physiological processes in distinct regions of the intestine, modulated by 
local pH. 
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Although guanylin-like peptides and GC-C appear to regulate fluid and electrolyte balance in 
intestine, the precise role of this receptor in normal intestinal physiology remains undefined. GC-
C exhibits broad phylogenetic expression, suggesting the existence of an evolutionary pressure 
mediating its conservation (20, 21). In intestine, GC-C is expressed along a crypt-to-villus 
gradient with the greatest expression in the mid-villus where enterocytes transition from 
proliferation to differentiation, suggesting that GC-C may play a role in regulating that transition 
(22, 23). Also, expression of GC-C is highly conserved, whereas that of guanylin is significantly 
reduced, in proliferating colorectal cancer cells and tumors (10, 24-27). In addition, oral 
uroguanylin reduced the formation of polyps in the Min/+ mouse model of colon cancer (27). 
Taken together, these observations suggest an association between GC-C and the regulation of 
enterocyte proliferation. 
In this study, regulation of human colon cancer cell proliferation by GC-C was examined in 
vitro. ST and uroguanylin inhibited the proliferation of human colon cancer cells by activating 
GC-C and stimulating accumulation of cGMP. Inhibition of intestinal cell proliferation by GC-C 
agonists reflected prolongation of the cell cycle in the absence of cell death. 
MATERIALS AND METHODS 
Reagents. DMEM, MEM containing Earle’s salts but not L-glutamine, L-glutamine, and other 
reagents for cell culture were obtained from Life-Technologies Inc. (Rockville, MD). FBS and 
DMEM/F12 were from Mediatech Inc. (Herndon, VA). Native ST and the inactive analog ST(5-
17) Ala
9,17
, Cys(Acm)
5,10
, 6-14 disulfide (TJU 1-103) were prepared by solid phase synthesis and 
purified by reverse phase HPLC, their structure confirmed by mass spectrometry, and their 
activities confirmed by examining competitive ligand binding and guanylyl cyclase activation. 
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Uroguanylin was obtained from Peninsula Laboratories (Belmont, CA). [methyl-
3
H]Thymidine 
(1 mCi/ml) was obtained from Amersham Pharmacia Biotech Inc. (Piscataway, NJ). ScintiVerse 
and DMSO were obtained from Fischer Scientific (Fair Lawn, NJ). IBMX, zaprinast, 8-Br-
cGMP, PI and all other chemicals were obtained from Sigma Chemical Co. (St. Louis, MO). 
Cell culture. Cell lines were obtained from the American Type Culture Collection (Manassas, 
VA) and grown in DMEM/F12, containing 2.5 mM L-glutamine, 100 IU/ml penicillin, 100 
g/ml streptomycin, and 10% FBS. Cells were maintained at 37ºC in a humidified atmosphere of 
5% CO2, fed with fresh medium every third day and split when sub-confluent. Caco2 cells were 
used at passages 25-35, T84 at passages 45-60 and SW480 at passages 100-110. Cells were used 
during their logarithmic growth phase.  
Cell proliferation. Cell number was quantified on a hemocytometer following trypsinization and 
staining with trypan blue. Protein concentrations were quantified using BCA reagent (Pierce, 
Rockford, IL). 
3
H-Thymidine incorporation into DNA was quantified by incubating cells in 96 
well plates with 0.2 µCi/well of 
3
H-thymidine. Following incubation, media was aspirated, cells 
were incubated for 15 min with ice-cold 10% TCA and rinsed sequentially with 10% TCA and 
100% methanol. The acid-insoluble material containing 
3
H-labeled DNA was solubilized in 100 
µL of 0.2 N NaOH, 80 µL aliquots were dissolved in 1 ml ScintiVerse and radioactivity 
quantified in a Packard -scintillation spectrometer. In experiments examining the effects of FBS 
stimulation on cell proliferation, cell numbers were quantified on 60 mm dishes of exponentially 
growing cells (~60% confluent) at time 0 (t0) and after 48 h of treatment with ST (1 µM) or PBS. 
Proliferation of cells stimulated with FBS was quantified in 96 well plates at a density of 
~50,000 cells/well. Six h after seeding cells were synchronized by FBS starvation in DMEM for 
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18 h, followed by stimulation for 24 h in media containing 10% FBS, in the presence or absence 
of the indicated reagents. 
3
H-Thymidine was added during the last 3 h of treatment and 
incorporation into DNA quantified as described above. In experiments examining the effects of 
L-glutamine, exponentially growing T84 cells (~60% confluent) in 60 mm dishes (cell numbers) 
or in 96 well plates (
3
H-thymidine uptake) were starved in MEM for 24 h. At this point (t0), fresh 
MEM containing 10 mM L-glutamine was added, with ST (1 µM) or PBS. Cell numbers were 
quantified at t0 and after 48 h of treatment. Proliferation was assessed by quantifying 
3
H-
thymidine incorporation after 12, 24 and 48 h. 
Cell cycle kinetics. For flow cytometry, T84 cells were plated in 6-well plates (~10
6
 cells per 
well). At 24, 48 and 72 h, cells were placed in suspension by trypsinization, pelleted by 
centrifugation, washed with PBS, and fixed in 500 µL ice-cold 75% ethanol for 30 min. After 
another wash with PBS, cell were resuspended in 500 µL of staining solution (50 µg/mL PI, 100 
µg/mL RNase A, 1 mM EDTA and 0.1% Triton X-100), and analyzed on a Coulter EPICS XL-
MCL flow cytometer. Distribution in different phases of the cell cycle was analyzed using 
WinMDI software (version 2.8) provided by Joseph Trotter, Scripps Research Institute (La Jolla, 
CA). Twenty thousand cells, cleared from doublets, were analyzed from each sample. The 
influence of ST on the S phase of the cell cycle was investigated employing exponentially 
growing cells (~60% confluent, in 96 well/plates) that were synchronized in MEM for 48 h and 
then stimulated with 10 mM L-glutamine (in MEM) for the indicated times, in the presence of 
ST (1 µM) or PBS. 
3
H-Thymidine (0.2 µCi/well) incorporation into DNA during the last 2 h of 
incubation was assessed as described above. In experiments examining the latency of the ST 
effect, T84 cells were pulse-labeled with 
3
H-thymidine for the last 3 h of a 24 h period of 
stimulation with L-glutamine. ST (1 µM) or PBS was added 15 min before 
3
H-thymidine to 
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investigate the impact of short treatment duration on the proliferative fraction of the cell 
population.  
Cell death. Exponentially growing T84 cells in 60 mm dishes were starved in MEM for 24 h. At 
this point, fresh MEM containing 10 mM L-glutamine was added, together with either 1 M ST, 
1 M uroguanylin or PBS. After 24 h, cells were collected by trypsinization and pelleted, and 
apoptotic cell death was determined by TUNEL analysis, employing the Flow-TACS Kit (R&D 
Systems, Minneapolis, MN). One million cells per condition were fixed in 3.7% formaldehyde 
solution and biotinylated dNTPs incorporated into the 3  ends of fragmented DNA (28) were 
stained with fluorescein isothiocyanate (FITC)-conjugated streptavidin. Cells were co-stained 
with PI and analyzed by flow cytometry within 1 h. In some experiments, apoptosis was assessed 
by DNA fragmentation analysis (27).  Briefly, 2 x 10
5
 T84 cells were seeded into 35 mm dishes 
and cultured for 7 d in DMEM/F12 containing 10% FBS. Pre-confluent monolayers were washed 
with serum- and antibiotic-free DMEM, incubated in that media for 16 h, washed, and then 
incubated for 2 h in DMEM supplemented with either PBS, DMSO, 10 M uroguanylin, 1 M 
ST, 1 mM IBMX, 10 M uroguanylin plus 1 mM IBMX, or 1 M ST plus 1 mM IBMX. DNA 
was isolated from cells collected by trypsinization, washed twice with PBS, and resuspended in 
200 l PBS (DNA Fragmentation Analysis Kit; Roche, Indianapolis, IN). DNA was analyzed by 
electrophoresis in 1.8% NuSieve 3:1 agarose (BMA, Rockland, ME) with ethidium bromide. 
Cell death mediated by necrosis was assessed by flow cytometry, as outlined above, trypan blue 
exclusion and lactate dehydrogenase release.  
Cyclic nucleotide assays. Accumulation of cGMP and cAMP were determined in exponentially 
growing T84 cells (~60% confluent, 96 well/plates) following 3 h of exposure to 1 M ST or 
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PBS. Briefly, cells were starved in MEM for 24 h and stimulated with 10 mM L-glutamine 
(MEM) for 21 h, ST (1 M) or PBS was added and cells incubated for an additional 3 h at 37ºC.  
The media was aspirated and reactions terminated by the addition of 200 µL/well of a lysis 
buffer containing 0.5% dodecyltrimethylammonium bromide. Aliquots (100 µL) of each lysate 
were processed for quantification of cGMP or cAMP by enzyme-immunoassay (Amersham 
Pharmacia Biotech Inc., Piscataway, NJ). 
Statistics. All determinations were performed at least in duplicate, experiments were performed 
at least in triplicate, and data are expressed as mean ± SEM. Data were analyzed employing the 
paired two-tailed Student’s t-test, and significance was assumed at p<0.05. 
RESULTS 
ST inhibits proliferation of human colon carcinoma cells induced by serum. ST (1 M) 
reduced proliferation induced by serum ~75 %, quantified by protein content and/or cell number, 
of T84 (protein content: PBS, 71.56% ± 9.29 vs ST, 12.29 % ± 1, p<0.05; cell number: PBS, 
91.49 % ± 7.12 vs ST, 23.4 % ± 3.63, p<0.01) and Caco2 (cell number: PBS, 105.26 % ± 8.1 vs 
ST, 36.84 % ± 2.83, p<0.01) human colon carcinoma cells, which express GC-C (Fig. 1A). 
Proliferation induced by serum of SW480 human colon carcinoma cells, which do not express 
GC-C (29), was not affected by ST. Similarly, ST (1 M) reduced 
3
H-thymidine incorporation 
into the DNA of T84 cells to 5.94 % + 2.13 of controls (p<0.001) and Caco2 cells to 62.2 % + 
12.43 of controls (p<0.05), but not that of SW480 cells, after serum stimulation (Fig. 1B). The 
cell permeant analog of cGMP, 8-Br-cGMP, the downstream effector of ST, inhibited 
proliferation of SW480 cells stimulated by FBS to 75.78 %  0.64 of the control (p<0.01, data 
not shown). The differential effect of ST on 
3
H-thymidine incorporation likely reflects the 
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greater density of GC-C on T84 compared to Caco2 cells (29). ST inhibited 
3
H-thymidine 
incorporation in T84 cells in a concentration-dependent fashion with a Ki (14.4 ± 1.6 nM; Fig. 
1C), comparable to the Ka of that ligand for GC-C (30, 31). 
ST inhibits proliferation of T84 cells induced by L-glutamine. L-glutamine induces human 
intestinal cells to proliferate (32, 33). Proliferation of T84 cells stimulated by 10 mM L-
glutamine, quantified by cell number, was inhibited by 1 M ST (PBS, 171.41 % ± 7.98 vs ST, 
92.74 % ± 11.54, p<0.05). ST inhibition of proliferation induced by glutamine was comparable 
to that observed with cells stimulated by serum (Fig. 2A). ST inhibition of proliferation induced 
by glutamine was associated with a time-dependent reduction in DNA synthesis, quantified by 
assessing 
3
H-thymidine incorporation (Figs. 2B, 2C). 
ST reduces the rate of DNA synthesis in T84 cells. Progression through the cell cycle, assessed 
by flow cytometry, of T84 cells synchronized by starvation and subsequently induced to 
proliferate by FBS (24 h) was not altered by ST (Fig. 3A). Identical results were obtained with 
T84 cells growing asynchronously, or synchronized by starvation and induced to proliferate by 
L-glutamine for 12, 24, 48 and 72 h (data not shown). It is particularly noteworthy that the 
proportion of cells identified by flow cytometry in the sub-G1 fraction, which reflects cells 
undergoing apoptosis or necrosis, was identical to incubations containing ST or PBS (Fig. 3A). 
However, ST shifted to the right the time course of 
3
H-thymidine incorporation into DNA of T84 
cells stimulated by L-glutamine, and caused a decrease in its maximum incorporation (Figs. 3B1, 
3B2). Double reciprocal analysis of these data revealed that ST delayed 
3
H-thymidine 
incorporation, and consequently synthesis of DNA, by ~4 h (Fig. 3B2). 
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The antiproliferative effect of ST does not reflect cell death. Inhibition by 1 M ST or 
uroguanylin of proliferation induced in synchronized T84 cells by L-glutamine was not 
associated with DNA fragmentation, assessed by TUNEL analysis (Fig. 4A). There were no 
differences in the percentages of apoptotic cells in cultures incubated with ST or uroguanylin 
compared to PBS (Fig. 4B). A recent report suggested that uroguanylin induced apoptosis in T84 
cells (27).  However, there were no differences in DNA fragmentation in T84 cells processed as 
described in that earlier report and exposed to DMSO, 10 M uroguanylin, 1 M ST, 1 mM 
IBMX, 10 M uroguanylin plus 1 mM IBMX, or 1 M ST plus 1 mM IBMX (Fig. 4C), in close 
agreement with results obtained in the present study by TUNEL analysis. Examination of trypan 
blue exclusion and lactate dehydrogenase release confirmed that the antiproliferative effect of 
GC-C agonists in T84 cells was not mediated by cell necrosis (data not shown).  
The anti-proliferative effects of ST are mediated by cGMP. The concentration-dependence of 
inhibition of 
3
H-thymidine incorporation into T84 cells was identical following incubation with 
ST for 15 min or 21 h before pulse-labeling with 
3
H-thymidine, consistent with the hypothesis 
that the antiproliferative effect of that ligand is an immediate response (compare Figs. 1C and 
5A). Also, uroguanylin, an agonist with lower potency for binding to and activating GC-C 
compared to ST (18, 19), inhibited 
3
H-thymidine incorporation into DNA of T84 cells with a 
lower potency (Ki = 141 ± 45 nM) than ST (Ki = 13.7 ± 5.2 nM; Fig. 5A). In addition, 1 M ST 
induced accumulation of cGMP, but not cAMP, in T84 cells concurrently with the effects of that 
ligand on proliferation (Fig. 5B). Finally, 8-Br-cGMP (5 mM) and the cGMP-specific PDE5 
inhibitor zaprinast (10 M), but not the inactive ST analog TJU 1-103 (1 M), mimicked the 
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antiproliferative effect of 1 M ST or uroguanylin (Fig. 5C). Zaprinast (10 M) potentiated the 
antiproliferative effect of 1 M ST, presumably by increasing the accumulation of cGMP (34). 
DISCUSSION 
GC-C is the receptor for the family of homologous STs that mediate secretory diarrhea in 
travelers, under-developed countries, and farm animals worldwide (1-4).  Expression of STs 
reflects molecular mimicry by bacteria, exploiting signaling pathways in the mammalian 
gastrointestinal tract to secure an evolutionary advantage. STs are structurally and functionally 
homologous to guanylin and uroguanylin elaborated in mammalian intestine (14-17). Although 
these peptides are endogenous GC-C agonists, their precise role in intestinal physiology has 
remained undefined. One hypothesis suggests a role for these peptides in the paracrine and 
autocrine regulation of fluid and electrolyte homeostasis in the intestine. Also, these peptides are 
expressed in extra-intestinal sites, including the kidney, suggesting that they may comprise one 
limb of an endocrine feedback loop that integrates the intestine into mechanisms regulating 
volume homeostasis (18, 19). This function for GC-C is analogous to that for GC-A and GC-B 
and their agonists, the natriuretic peptides, which regulate fluid and electrolyte secretion in the 
kidney and play a central role in volume homeostasis (11).  
Also, GC-C may regulate processes other than fluid and electrolyte secretion in the intestine. Of 
significance, natriuretic peptides inhibit proliferation in human cell lines by interacting with 
guanylyl cyclase receptors and inducing accumulation of cGMP (35-37). Similarly, cGMP 
inhibits proliferation in several cell lines (38-41). Cyclic GMP delays the G1/S transition in 
human vascular smooth muscle cells (42). In addition, exisulind, which inhibits cGMP-specific 
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PDE, induces apoptosis in human colon cancer cells in vitro (43, 44). Furthermore, recent studies 
suggest that uroguanylin induces apoptosis in T84 and Caco2 human colon cancer cells (27). 
Thus, in some cell systems, including human intestine, guanylyl cyclases and cGMP may 
regulate cell proliferation and/or apoptosis (42, 45, 46). 
The present study examined the role of GC-C and cGMP in regulating proliferation in human 
colon cancer cells. Proliferation was induced by serum (10%), and by L-glutamine (10 mM), a 
specific mitogen for intestinal cells (32, 33). ST inhibited proliferation of T84 and Caco2 cells in 
a concentration-dependent fashion with nanomolar potency. This effect was specifically 
mediated by GC-C, since proliferation was also inhibited by uroguanylin, a GC-C agonist, but 
not by an inactive analogue of ST. Similarly, ST did not affect proliferation of SW480 cells, 
colon carcinoma cells that do not express GC-C nor exhibit ST-induced accumulation of 
[cGMP]i (29). The effect of GC-C agonists on proliferation was an immediate response mediated 
by activation of the catalytic domain of GC-C and accumulation of cGMP. ST-induced inhibition 
of proliferation was graded with respect to the density of GC-C expressed on the cell surface and 
to the accumulation of [cGMP]i (29). Proliferation of T84 cells, which express the largest 
number of surface GC-C molecules, exhibited the greatest inhibition of proliferation compared to 
Caco2 cells, which express ~80% fewer GC-C molecules on their surface and accumulate about 
ten times less cGMP after ST treatment (29). ST induced the accumulation of cGMP, but not 
cAMP, in target cells over the time course in which proliferation was inhibited. 8-Br-cGMP, the 
cell-permeant analogue of cGMP, had identical effects on T84 and Caco2 proliferation compared 
to ST and uroguanylin, and inhibited the proliferation of SW480 cells stimulated by FBS. 
Finally, the effects of GC-C agonists on proliferation were mimicked and potentiated by 
zaprinast, a selective inhibitor of cGMP-regulated PDE5 that induces accumulation of [cGMP]i, 
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potentiating ST stimulation of guanylyl cyclase activity in T84 cells (34, 47). Taken together, 
these data support the hypothesis that ST and uroguanylin regulate proliferation of human 
intestinal cells by binding to and activating GC-C, inducing the accumulation of cGMP. 
Treatments that selectively raise [cGMP]i, including ST, uroguanylin, or PDE inhibitors, alone or 
in combination with GC-C agonists, did not induce apoptosis in human colon cancer cells, 
assessed by TUNEL and DNA fragmentation analyses during various phases of growth and 
employing different proliferative agents. These observations are in contrast to those reported 
recently concerning the induction of apoptosis in T84 and Caco2 cells by uroguanylin (27). 
However, the earlier study quantified apoptosis by manually counting small numbers of cells 
whereas the present study employed flow cytometric analysis of >20,000 individual cells for 
each determination. In addition, these data contrast with those obtained with exisulind, which 
inhibits cGMP-specific PDEs and induces apoptosis in human colon carcinoma cells (43, 44). 
The inability to induce apoptosis of colon cancer cells by agonists that elevate [cGMP]i, cell-
permeant analogs of that nucleotide, or inhibitors of cGMP-specific PDE5, demonstrated herein, 
suggests that exisulind may have multiple effects in tumor cells and may induce apoptosis 
through cGMP-independent mechanisms.  
Whereas GC-C agonists did not induce apoptosis in colon cancer cells, these agonists delayed 
their progression through the cell cycle. While ST inhibited proliferation assessed by a variety of 
measures, flow cytometry demonstrated that this agonist did not alter the fraction of cells in any 
phase of the cell cycle. Specific examination of S phase by pulse analysis of 
3
H-thymidine 
incorporation into DNA of synchronized colon cancer cells revealed that ST delayed DNA 
synthesis and prolonged that phase of the cell cycle. Taken together, these data suggest that GC-
 14 
C agonists induce a generalized delay in the progression of colon carcinoma cells through, 
without arrest in a specific phase of, the cell cycle (48). Indeed, equation 1 (49): 
N  =  N02
T/mgt
   
where N is the final cell number (PBS-treated cells: 13.7 x 10
5
  4.57; ST-treated cells: 9.4 x 10
5
 
 1.42), N0 is the initial cell number (3.9 x 10
5
  1.57), T is the elapsed time (44 h), and mgt is 
the mean generation time, supports the suggestion that GC-C agonists increase the duration of 
the cell cycle of T84 cells stimulated by FBS 40 %, from 26.9  9.52 h to 37.31  14.6 h (n=6, 
p<0.05). These observations demonstrate that GC-C agonists are cytostatic, rather than cytotoxic, 
with respect to human colon carcinoma cells. 
The precise mechanisms by which GC-C agonists delay progression of colon carcinoma cells 
through the cell cycle remain incompletely defined. Molecular targets for cGMP in those cells 
include PKGII (50), PDE3 (13), and PKA (51). While activation of PKGII would mediate 
cGMP-selective regulation of fluid and electrolyte transport or phosphorylation of proteins 
involved in cell cycle regulation, inhibition of PDE3 or activation of PKA would ultimately 
result in functional transactivation of cAMP-regulated processes. The cytostatic effects of GC-C 
agonists, 8-Br-cGMP, and zaprinast described herein suggest that their actions are mediated 
through cGMP-specific downstream effectors rather than transactivation of cAMP-dependent 
mechanisms. The mechanisms by which cGMP regulates progression through the cell cycle, 
without specific effects on a particular phase of that cycle, remain undefined, although this 
phenomenon has been observed previously (48). 
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In conclusion, agonist activation of GC-C regulates the proliferation of colon carcinoma cells by 
slowing progression through the cell cycle without inducing cell death. These data suggest that 
GC-C and its endogenous agonists, guanylin and uroguanylin, may play a role in regulating the 
transition between intestinal stem cell proliferation and their differentiation into mature 
enterocytes (52). Additionally, they support the suggestion that GC-C agonists may represent 
novel cytostatic agents for the prevention and treatment of colorectal cancer.
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FIGURE LEGENDS 
Figure 1. A. T84, Caco2 or SW480 cells, induced with 10% FBS, were incubated for 48 h with 1 
M ST () or PBS () and then protein and/or cells were quantified as described in Methods. 
Values are expressed as the % increase in cell number or protein stimulated by FBS relative to 
those values at t0 (baseline). Total cells at t0 were: T84, 4.7 x 10
6
 ± 0.2; Caco2, 1.8 x 10
6
 ± 0.4; 
and SW480, 3.3 x 10
6
 ± 0.4. T84 protein content at t0 was 0.5 ± 0.02 mg/mL. B. T84, Caco2, and 
SW480 cells were synchronized 6 h after seeding by starvation for 18 h and then stimulated with 
10% FBS for 24 h in the presence of 1 M ST () or PBS (). After 21 h, 3H-thymidine was 
added to the media and incubation continued for another 3 h. 
3
H-Thymidine incorporation into 
DNA was quantified as described in Methods. Values are expressed as a % of the 
3
H-thymidine 
incorporation stimulated by FBS in the presence of PBS. C. T84 cells were synchronized by 
starvation, stimulated to proliferate by addition of 10% FBS, and exposed to 
3
H-thymidine and 
the indicated concentrations of ST, as described in (B). Following 24 h of incubation, 
3
H-
thymidine incorporation into DNA was quantified as described in Methods. *, p<0.05; **, 
p<0.01; ***, p<0.001. 
Figure 2. A. T84 cells were synchronized by starvation in MEM depleted of L-glutamine for 24 
h. Proliferation was stimulated with MEM containing 10 mM L-glutamine; cells were incubated 
for 48 h with 1 M ST or PBS, and quantified as described in Fig. 1A. Values are expressed as 
the % increase in cell number stimulated by L-glutamine relative to those values at t0. Total cells: 
at t0 = 0.4 x 10
6
 ± 0.07; at 48 h, control = 1.4 x 10
6
 ± 0.2; ST = 0.9 x 10
6
 ± 0.06. B. Cells were 
synchronized, stimulated to proliferate by glutamine (as described in panel A), and 
3
H-thymidine 
and 1 M ST () or PBS () were added and incubated for the indicated times. At the 
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conclusion of incubations, 
3
H-thymidine incorporation into DNA was quantified as described in 
Methods. Values reflect a representative experiment. In panel (B2), data obtained in panel (B1) 
are expressed as {100-[(
3
H-thymidine incorporation in ST-treated incubations)/(
3
H-thymidine 
incorporation in control incubations) x 100]}.  *, p<0.05; **, p<0.01. 
Figure 3. A. T84 cells were synchronized 6 h after seeding by starvation and then stimulated to 
grow by adding 10% FBS in the presence of 1 M ST or PBS. After 24 h, cells were trypsinized, 
pelleted, and then fixed and stained with PI. Fluorescence analysis of DNA content was 
performed as described in Methods and the % of cells in each phase of the cell cycle is 
represented. Data are from a representative experiment. Following synchronization by starvation 
(t0), 75.7 % ± 4.5 of T84 cells were in the G0/G1 phase of the cell cycle. B1. T84 cells were 
synchronized by starvation in MEM depleted of L-glutamine for 48 h, stimulated to proliferate 
with MEM containing 10 mM L-glutamine, and incubated for the indicated time points with 1 
M ST () or PBS (). 3H-thymidine was added for the last 2 h of incubation and the 3H 
incorporated into DNA was measured as described in Methods. Data reflect a representative 
experiment. Results from 3 experiments performed as described in panel (B1) are presented in 
panel (B2) as mean ± SEM. *, p<0.05. 
Figure 4. A. T84 cells were synchronized and stimulated to proliferate by L-glutamine, as 
described in Fig. 2A, with simultaneous addition of 1 M ST, 1 M uroguanylin (URO), or PBS 
(CTR).  Incubations were continued for 24 h and cells were trypsinized and pelleted, divided in 1 
x 10
6
 aliquots, fixed and permeabilized using Cytonin™ reagent. Biotinylated DNA was co-
stained with both FITC-conjugated streptavidin and PI. The positive control (TACS) was 
generated using the TACS-Nuclease™ provided with the FlowTACS kit. Flow cytometry 
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analysis was performed as described in Methods and data were plotted in two-dimensional 
format. Data are from a representative experiment. B. Mean ± SEM of the % of FITC-positive 
T84 cells (apoptotic/necrotic) from three experiments performed as in panel (A). C. T84 cells 
(seeded at a density of 2 x 10
5
 into 35 mm dishes) were cultured for 7 d in DMEM/F12, plus 
10% FBS. Pre-confluent monolayers were washed with DMEM (4.5g/L glucose, containing L-
glutamine) and incubated in that media for 16 h. Cells were washed again in DMEM and then 
incubated for 2 h in that media supplemented as described in Methods (vehicle: PBS or DMSO; 
uroguanylin: URO). DNA was analyzed as described in Methods. The U937 positive control 
DNA was provided in the fragmentation analysis kit. Data are from a representative experiment. 
Figure 5. A. Cells were synchronized and proliferation stimulated by L-glutamine, as described 
in Fig. 2A, and 21 h later cells were exposed to PBS or the indicated concentrations of ST ( ) or 
uroguanylin (o). Following 15 min of incubation, 
3
H-thymidine was added to the media and 
incubation continued for another 3 h. 
3
H-Thymidine incorporation into DNA was determined as 
described in Methods. B. Cells were synchronized, stimulated to proliferate and exposed to 1 
M ST () or PBS (), as described in panel (A). After 3 h of incubation, media was aspirated 
and cGMP and cAMP were quantified as described in Methods. Data from a single experiment 
are expressed as fold accumulation in ST- compared to PBS-treated cells (control; CTR). C. 
Cells were synchronized, stimulated to proliferate and pulse labeled with 
3
H-thymidine, as 
described in panel (A), and 15 min later T84 cells were exposed to PBS (CTR), 1 M TJU 1-103 
(TJU), 1 M ST, 1 M uroguanylin (URO), 5 mM 8-Br-cGMP, 10 M zaprinast (ZAP), or 1 M 
ST plus 10 M zaprinast. Following 3 h of incubation, 
3
H-thymidine incorporation into DNA 
was quantified as described in Methods. Results are the mean ± SEM of a representative 
experiment performed in triplicate. *, p<0.05; **, p<0.01; ***, p<0.001. 
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